ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA

ImmunityBio (IBRX) shares rose about 26% after the FDA outlined a potential resubmission path for ANKTIVA in BCG-unresponsive papillary non-muscle invasive bladder cancer, saying additional information is needed to support a supplemental Biologics License Application but no new clinical trials are required, a development investors view as de-risking the regulatory process and potentially enabling a broader label. Trading volume surged on Nasdaq amid the regulatory update and ongoing volatility around ANKTIVA’s commercialization prospects.